Public health plan for the pharmaceutical treatment of Hepatitis C. by unknown
                                                      
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Public Health 
Plan for the 
Pharmaceutical 
Treatment of 
Hepatitis C 
 
December 2014 
 1 
 
Contents 
1. Introduction……………………………………………………………………...............2 
 
2.   The Scale of the Problem………………………………………………………………..4 
2.1 Epidemiology of hepatitis C……………………………………………….................4 
2.2 Burden of disease………………………..…………………………………………...7 
 
3. Management of Patients with hepatitis C……………………………………………..11  
3.1 Prevention of Infection……………………………………………………................11 
3.2 Screening for hepatitis C………………………………………………………….….11 
3.3 Strategies to Treat hepatitis C………………………………………………………..12 
3.4 The Irish Hepatitis C Outcomes Research Network (ICORN……………………….13 
3.5 Standard treatment regimens………………………………..…………….................14 
3.6 New drug regimens………………………………………………………..................14 
3.7 Cost impact and affordability………………………………………………………..15  
 
4. Drug Reimbursement Decision Process in Ireland…………………………..……….21 
4.1 Health Technology Assessment……………………………………………………...21 
4.2 Drug Reimbursement Process………………………………………………………..22 
 
5. Proposed Multi-annual Pharmaceutical Treatment Plan……………………………23 
5.1 Feasibility of a Multi-annual Treatment Plan based on Clinical Prioritisation…..…..23 
5.2 Clinical Management of Patients with hepatitis C…………………………………...26 
5.3 Governance and management of a Hepatitis C Treatment Programme……………...28 
 
6. Conclusions…………………………………………………………….………………..35 
 
7. References……………………………………………………………………………….37 
 
 
Appendix 1: Terms of Reference for the Group………………………………………….40 
 
Appendix 2: Membership of the Group…………………………………………………...41 
 
 
 
 
 
 
 
 
 
 2 
 
1. Introduction 
In Ireland and in other countries hepatitis C infection is recognised as a significant public 
health problem with its associated burden of managing and treating the disease on 
individuals, their families, health services, communities and society. 
  
Hepatitis C became a notifiable disease in Ireland in 2004 and between then and 2013, 12,333 
cases were notified with a peak in 2007 (n=1539). In recent years there has been a significant 
decrease in notifications with 847 cases notified in 2013.  Studies to estimate the prevalence 
of chronic hepatitis C in the population have been carried out over the last few years. A study 
in 2009 estimated the national prevalence of chronic hepatitis C as 0.5-1.2% (20,000-50,000) 
while more recent information indicates prevalence is likely to be 0.5-0.7% (20,000-30,000). 
However although there has been a recent decrease in notifications there is still a significant  
burden associated with advanced stage hepatitis C infection  including liver disease, liver 
failure, liver cancer requiring for some transplant and death.   
 
In Ireland the main route of transmission is through sharing of needles and drug paraphernalia 
by people who inject drugs. In notified cases when data was available 75% of the cases of 
hepatitis C were in people who inject drugs. In the past transmission occurred primarily 
through infected blood products. 
 
Viral eradication prevents disease progression. Until 2011 the standard treatment for people 
with hepatitis C infection was dual therapy interferon and ribavirin. This treatment led to a 
variable response but was associated with significant side effects, particularly from 
interferon. Recently new pharmacological treatment regimens have been developed which 
have demonstrated high rates of viral clearance in clinical trials.  These new drug regimens 
are at various stages of development and regulatory approval. Some have been licensed and 
others are expected to be in the near future. Those licensed in the EU include sofosbuvir, 
daclatasvir and simeprevir. These drugs are commonly used in combination with other drugs 
for example Sofosbuvir  +/- daclatasvir +/- ribavirin.  Currently in Ireland a number of these 
new drug regimens are going through the assessment process for reimbursement in the HSE.  
Internationally there is an increasing focus on these new drug treatments. They are recognised 
as clinically effective treatments with significantly improved treatment outcomes and fewer 
side effects, however the cost of these drugs is resulting in a significant burden on health care 
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systems worldwide. A number of diverse strategies have been implemented by different 
countries to address these issues of affordability; with many adopting the approach of 
prioritisation based on clinical need of infected patients. Following these important 
developments in the area of new and emerging treatment regimens for hepatitis C, the Chief 
Medical Officer, in the Department of Health established a group to advise the Minister for 
Health through the office of the Chief Medical Officer. 
 
The role of this advisory group was to advise on the feasibility of a multiannual public health 
treatment plan for patients with hepatitis C infection based on clinical prioritisation criteria 
for identification of patients for each treatment phase. The Advisory group included patient 
advocates, clinicians, the National Centre for Pharmaco-economics (NCPE), HIQA, the HSE 
and officials from the Department of Health and is chaired by the CMO’s office (Appendix 
1).  
 
After reviewing the evidence on clinical and cost effectiveness and the budget impact of the 
new drug regimens, the Group advised on the development of a treatment strategy. This 
treatment strategy’s implementation will over the next few years aim to increase the number 
of people with hepatitis C infection being treated effectively with complete clearance of the 
virus and reduce the numbers of people in the community with hepatitis C.  The 
implementation of the treatment strategy is an important component in ultimately working 
towards eradication of hepatitis C in the Irish population.  
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2. The Scale of the Problem 
2.1 Epidemiology of hepatitis C 
Hepatitis C, a small single stranded RNA virus of the Flaviviridae family, was first identified 
in 1989. There are six distinct genotypes.
(1)
 Hepatitis C is a bloodborne virus which can be 
transmitted through equipment sharing when injecting drugs or through receipt of 
contaminated blood and blood products and less commonly can be transmitted 
occupationally, sexually and through vertical transmission from mother to child.
(1)
 
Worldwide, it is estimated that three to four million people are newly infected each year and 
that approximately 170 million people are currently chronically infected and at risk of 
developing liver disease, including cirrhosis and hepatocellular carcinoma (HCC).
(2)
 
 
In 2004, hepatitis C was added to the list of notifiable diseases in Ireland. Between 2004 and 
2013, 12,148 cases of hepatitis C were notified. The number of notifications peaked in 2007 
(n=1539) with a marked decrease in recent years. In 2013, 786 cases were notified nationally 
(personal communication, Lelia Thornton, HPSC). In 2012, the case definition was altered to 
specifically exclude resolved cases of hepatitis C which may explain part of the reduction in 
the number of cases notified after this date. The trend analysis of the notification of hepatitis 
C by age and sex is shown in figure 1 below. 
 
Since 2010 in Ireland, risk factor information has been available for 57% of notified cases of 
hepatitis C and of these, 83% were people who injected drugs. Genotypes 1 and 3 are the 
types  most commonly seen in Ireland
(3)
. Genotype 1 traditionally has been the most difficult 
to treat
(4)
.  
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Figure 1 Number of notifications of hepatitis C in Ireland 2004-2013, by sex and mean age 
 
(Source: HPSC)  
 
Although there were no notifications of hepatitis C prior to 2004, diagnostic data from the 
National Virus Reference Laboratory (NVRL) are available. Approximately 10,000 
individuals were diagnosed with hepatitis C by the NVRL between 1989 and 2004. Some 
cases of hepatitis C that were diagnosed prior to it becoming notifiable in 2004 may have 
been notified since 2004, so there is potentially considerable overlap between the NVRL 
diagnostic data and HPSC notifications data. A study combining NVRL and HPSC 
notifications data, and taking this overlap account and also adjusting for undiagnosed cases, 
estimated the prevalence of chronic hepatitis C in Ireland at the end of 2009 to be between 
0.5 and 1.2% of the population (approximately 20,000-50,000 people).
(3) 
 This allowed for 
under-diagnosis levels ranging from 50 to 80%. Evidence of lower levels of hepatitis C 
under-diagnosis (48%) from recent Scottish data
 
indicate that the true prevalence in the Irish 
population is likely to be closer to 0.5% (approximately 20,000 people).
(5)
  
 
However these are estimates of prevalence and the true prevalence rate in Ireland is 
unknown. There is no general screening of the population to determine prevalence rates with 
most studies only assessing the prevalence within specific risk groups. To date a national 
sero-prevalence study has not been undertaken. 
 
The estimates of prevalence however do indicate that in the general population the prevalence 
of hepatitis C is low and most cases are from a defined risk group e.g. people who inject 
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drugs, people who received unscreened blood or blood products and people who were born in 
hepatitis C endemic countries.  
 
A number of studies of specific risk groups have reported various levels of hepatitis C in 
these groups. For example, studies of people who inject drugs (mostly heroin users) in 
Ireland, between 1992 and 2006 reported a hepatitis C antibody (anti-HCV) prevalence in this 
population of between 52-84%.
(6-14)
 A prison study in 2011 determined that 54% of prisoners 
with a history of injecting heroin were anti-HCV positive and 41.5% of prisoners with a 
history of injecting any drugs were anti-HCV positive.
(15)
 
 
A study of asylum seekers attending the Balseskin reception centre indicated that 1% of those 
tested under the voluntary health screening programme between 2004 and 2012 were positive 
for chronic HCV infection.
(16)
 
 
Currently in Ireland the largest risk group for hepatitis C are people who inject drugs 
(PWIDs). In the past, transmission has occurred through infected blood and blood products 
with the majority of these infections occurring between the 1970s and the early 1990s. In 
1991 routine hepatitis C screening of blood donations in Ireland commenced. Approximately 
1,700 people were infected through blood and blood products in Ireland prior to the 
introduction of routine screening. However, as already noted the main route of transmission 
in Ireland was and continues to be through the sharing of needles and drug paraphernalia by 
people who inject drugs. Most new cases identified in Ireland are also in those who inject 
drugs (see figure 2 below). 
 
There may be a significant number of undiagnosed cases of HCV in the recent migrant 
population in Ireland.  Although asylum seekers are routinely offered infectious disease 
screening, there is no systematic testing for other migrants. At the time of the 2011 census, 
there were 766,770 non-Irish nationals living in Ireland. Based on census data on the number 
of people living in Ireland by country of birth (CSO unpublished data, CSO) and published 
data on the prevalence of anti-HCV by country of birth
(17)
  over 10,000 of these are likely to 
be chronically infected with HCV (personal communication: Niamh Murphy, HPSC). This 
assumes that the prevalence of HCV in the migrant population in Ireland is similar to 
published data for the general population in their country of birth.  
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Figure 2 Most likely risk factor (%) for cases of hepatitis C notified 2010-2013 (where data 
available, n=2354, 57%)  
 
 
(Source: HPSC) 
 
2.2 Burden of Disease 
Hepatitis C infection is often initially asymptomatic. However, approximately 75% of those 
infected fail to clear the virus and develop a chronic infection. Studies show that between 5 
and 20% of those chronically infected develop cirrhosis of the liver after 20 years of infection 
and that in patients with cirrhosis, 1.5% to 2.5% will develop hepatocellular carcinoma 
(HCC) each year. Up to 80% of those with  HCC will die each year.
(18)
 Once cirrhosis has 
developed, hepatic decompensation and other potentially fatal complications can occur 
requiring treatment and management including possibly liver transplantation. Associated with 
liver transplantation are many risks including rejection but there is also a risk that if the 
patient is not cleared of hepatitis C their transplant will become compromised due to 
reinfection.  
 
Within the public health system in Ireland there are a number of liver transplants carried out 
each year. The number depends on several factors including the number on the transplant 
waiting list and the availability of donors. Using the Hospital Inpatient Enquiry System 
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(HIPE) the number of transplants with a diagnosis of hepatitis C between 2005 and 2013 was 
89 cases. This would average approximately 10 cases a year
1
  
 
Figures on the number of deaths recorded with hepatitis C infection as cause of death are 
available from the Central Statistics Office (CSO). The accuracy of these figures is dependent 
on the accuracy and quality of death certification and it may be the case that there is 
underreporting. The number of deaths recorded on death certificates with chronic or acute 
hepatitis C is shown in Table1.  
Table 1: Deaths due to chronic or acute hepatitis C.2007 – 2012  
 
Year 
 
2007 
 
2008 
 
2009 
 
2010 
 
2011 
 
2012 
 
Deaths
2
 
 
7 
 
11 
 
14 
 
31 
 
19 
 
14 
Death due to specified ICD10 Codes B17.1 and B18.2 from 2007 - 2012 
(Source: CSO) 
 
Studies suggest that hepatitis C infection progresses faster in (i) males,(ii) those who are 
older at time of infection, (iii) people who are co-infected with HIV or hepatitis B and (iv) in 
those who consume high levels of alcohol.
(19, 20)
 Other factors that also influence disease 
progression include metabolic and genetic factors.
(21)
 
 
The clinical pathway of chronic hepatitis C infection is progression to fibrosis which if 
untreated can progress to cirrhosis. However the clinical course of HCV related cirrhosis is 
unpredictable. One study (n= 384) examining the clinical course of compensated cirrhotic 
patients over a 5-year period documented an annual incidence of decompensation and 
development of HCC of 4.4% and 2% respectively.
(22)
 The 3, 5, and 10-year survival rates 
were 96%, 91%, and 79%, respectively. In contrast patients presenting with a 
decompensation event (including ascites, portal hypertensive gastrointestinal bleeding, severe 
bacterial infection or encephalopathy) had a poorer outlook with survival rates of 81% and 
                                                          
1
 Note: Data are based on inpatient and day-case discharges from publicly funded acute hospitals with a 
principal or additional diagnosis of ICD-10-AM B17.1 [Acute hepatitis C] or B18.2 [Chronic viral hepatitis C], 
and a principal or additional procedure of ICD-10-AM ACHI 90317-00 [Transplantation of liver].
1
 
 
2
 Death due to specified ICD10 Codes B17.1 and B18.2 from 2007 - 2012 
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51% at 1 and 5 years. In addition the annual risk of developing HCC in this patient group was 
greater than 5% per annum.
(23)
 Another study examined the natural history of patients with 
HCV cirrhosis.
(24)
 The study examined the outcomes of 1050  patients  (60% advanced 
fibrosis and 40% cirrhosis) over an 8-year period. The results clearly demonstrate that 
patients with a decompensation event are at highest risk of death (35% risk of death within 2 
years) closely followed by patients with a Child Pugh Turcotte (CPT) score of greater than or 
equal to 7 on two consecutive visits (25% risk of death over 2 years). Among patients that 
had not decompensated platelet count correlated with decompensation events and mortality. 
The hepatitis C RNA level was also significantly related to clinical outcomes. 
 
Many of the studies on the progression of hepatitis C infection are based on data from other 
countries. However there is some information available on the progression of hepatitis C 
disease in patients in Ireland and some of this data with international data can be used in 
modelling studies to estimate the disease progression rates in Ireland. 
In estimating new cases it is important to note that the number of new cases of cirrhosis and 
HCC related to HCV in Ireland is dependent on the underlying prevalence, which is, as 
already identified somewhat uncertain. 
 
Based on the known information of the risk factors, and the exposure of the Irish population, 
together with the rates of progression of disease 
(25, 26)
 it is possible to estimate the likely 
burden of disease.  Using information from individual clinics, the National Cancer Registry 
of Ireland, and HIPE, together with some information on the likely prevalence and duration 
of disease it was possible to triangulate estimates of the expected number of cases that would 
be seen in coming years. Using results from this methodology it is projected that, without 
treatment, approximately 25-100 new HCV related cirrhosis cases and 5-25 new cases of 
HCC may be identified per annum. 
 
Figure 3 below seeks to illustrate the estimated numbers of those affected by hepatitis C and 
their engagement or not with the health services in Ireland whilst also demonstrating how the 
smallest cohort at the top of the pyramid have the most complex health needs and will be the 
high end users of the health system.  500 patients at the top of the pyramid are the patients 
with the most clinical need i.e. patients that have compensated or decompensated cirrhosis, 
low platelets and other accelerating factors. 
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Figure 3: Estimated numbers in population with chronic hepatitis C  
 
a  Estimated based on NVRL data, notification data , unpublished IDVU in treatment data, Irish official statistics and worldwide prevalence 
levels. 
b Approximate figures based on ICORN register and clinic information 
c. Approximate figure based on clinical information and application of clinical prioritisation criteria. 
 
 
 
  
500 Patients 
c
 
7,500
 b
 Patients  
diagnosed and engaged with 
services 
3,000 – 8,000
 
a 
Patients diagnosed and not engaged 
with services 
 
 
9,000 – 14,000a undiagnosed  
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3. Management of Patients with Hepatitis C 
 
3.1 Prevention of Infection 
Internationally strategies focus on prevention of infection through provision of information, 
education and harm reduction for example through provision of clean needles and drug 
paraphernalia. The HSE published the “National Hepatitis C Strategy 2011- 2014”. This 
strategy had a number of recommendations focused on education and prevention.  
 
Many of these strategies acknowledge that promotion of health literacy among groups at risk 
would be of benefit including for people who inject drugs (PWID). This information should 
include information on hepatitis C itself, its transmission, prevention, care and treatment 
options. Service providers are ideally placed to provide this information and “Health services 
should strengthen service providers knowledge and capacity to prevent and treat viral 
hepatitis in PWID” (27) 
 
Additional recommendations centre on the need for meaningful engagement with 
stakeholders in developing the strategies to provide information to their own peer group. Peer 
involvement at an early stage of a PWIDs drug using career has the potential to prevent new 
infection, promote testing for those at risk and provide practical support and information for 
those considering, or undergoing treatment.  
 
In the case of marginalised at risk groups there is a need for effective and meaning 
collaboration between hospitals based interventions and the specialist community/voluntary 
agencies, to promote optimal adherence rates and psychosocial well-being in the patient. 
 
3.2 Screening for hepatitis C 
Currently there is no universal population screening programme for hepatitis C in Ireland. 
However there is screening in place for patients attending services such as drug treatment 
services, sexual transmitted diseases services and maternity services and for specific 
populations for example prison services. 
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The prevalence of hepatitis C in the general population has not been determined although 
there is information, including recent information becoming available on the prevalence in 
different population groups.  
 
This was evidenced by a study which was undertaken in an Emergency Department of a large 
city centre Dublin hospital over a 20 week period in 2014. (personal communication, Colm 
Bergin, HSE) The study provided an opt-out screening programme for blood borne viruses. 
The hospital catchment area covers some of the most deprived areas of Dublin. The screening 
uptake of up 70% indicates that it is feasible and acceptable to patient and staff to carry out 
this screening. The study findings show that for 5,299 patients screened, 287 patients were 
hepatitis C positive with 44 of these cases being new diagnosis.  Of the patients previously 
known approx. 60 % were linked with the health services.  
 
Two studies that provided universal hepatitis C screening in two large maternity hospitals in 
Dublin found that  0.7 -0.9% were anti-HCV positive. 
(28, 29)
 Furthermore the Irish Blood 
Transfusion Service found that 0.02% of new donors tested between 1997 to 2012 were anti-
HCV positive (personal communication, IBTS).  
 
In Ireland the cost effectiveness of a universal population screening programme compared to 
alternative strategies has not been established. 
 
3.3 Strategies to treat Hepatitis C 
The research into treatment strategies for hepatitis C suggest that treating hepatitis C is cost 
effective at all levels of fibrosis. Studies looking at treatment regimens with interferon, 
ribavirin and triple therapy would also suggest that if there are constraints on the budget that 
treatment with these drug regimens is most cost effective in those with advanced liver disease 
thus supporting the use of clinical prioritisation. 
(31, 32) 
 
With the availability of these new drug treatments, research has focused on optimising 
treatment strategies. A recent study has shown that the total number of HCV infections is 
projected to decline in nearly every country studied due to a reduction in risk factors for new 
infections (e.g. screening of blood supply), aging of the infected population and the 
corresponding increase in mortality, and treatment of infected individuals.
(33)
 However even 
though the total number of infected individuals is expected to decline those who remain 
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infected are expected to progress to more advanced stages of liver disease and thus a sharp 
increase in HCC, liver related deaths, decompensated cirrhosis and cirrhosis cases are 
anticipated. The authors suggest that the hepatitis C burden will not be controlled by the 
current treatment strategies and that increased treatment and /or higher efficacy therapies 
would be needed to keep the number of hepatitis C individuals with advanced liver disease 
and liver-related deaths from increasing. 
 
Other research reviewing treatment strategies in different countries would propose that 
successful diagnosis and treatment of even a small number of patients can contribute 
significantly to a reduction in disease burden in those countries. 
(34) (44)
  The research would 
further suggest that the largest reduction in hepatitis C related morbidity and mortality occurs 
when increased diagnosis and treatment is combined with therapies with higher efficacy 
rates. This would require a significant increase in those being diagnosed and subsequently 
treated. This research also suggests that increased treatment and drug efficacy had most 
impact on morbidity and mortality when the patients being treated had more advanced 
fibrosis of the liver. However it also suggests that to have the largest impact on transmission 
of hepatitis C infection among active intravenous drug users requires treating all patients with 
any signs of fibrosis. To eliminate hepatitis C infection would require treating all these 
patients. The most effective treatment strategy was to treat those with more significant 
fibrosis (> F2
3
) and once that pool of patients had been depleted to expand to treat all patients 
including those with F0-F1. 
(34) 
 
This research would suggest that in order to manage the existing deteriorating cohort of 
patients in most countries a strategy for management of the disease will require the provision 
of screening for undiagnosed cases parallel to the treatment of patients 
 
3.4 The Irish Hepatitis C Outcomes Research Network (ICORN) 
The Irish Hepatitis C Outcomes Research Network (ICORN) is an interdisciplinary 
interagency network comprising hepatologists and infectious disease consultants, virologists, 
epidemiologists, scientists, patient representatives, HSE, pharmacists, nurses, health 
economists and health technology assessment experts. This cluster of clinical and research 
                                                          
3 METAVIR scoring system for liver fibrosis: F0, no fibrosis; F1, mild fibrosis; F2, moderate fibrosis ; F3,  severe fibrosis; F4, 
cirrhosis. 
(45)
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expertise overlying aim is to enhance the quality of care of patients with hepatitis C (HCV) 
whilst working towards and advocating for disease eradication over the coming decade – “C 
it off 2025”. The work of ICORN includes the assessment, development and evaluation of 
models of care, the development of clinical guidelines, the establishment of the ICORN 
Treatment Registry, and facilitating HCV clinical and laboratory research. 
 
3.5 Standard Treatment Regimens 
Hepatitis C treatment has evolved rapidly over the last 20 years. A cure is defined as a 
sustained virological response (SVR) and consists of undetectable levels of plasma hepatitis 
C virus RNA 12 or 24 weeks after completion of treatment.
(35) 
 
Initial clinical trials used interferon monotherapy. These were followed by the addition of 
ribavirin (RBV)  with pegylated interferon-α (peg-IFN) which showed improved SVR rates 
through the 1990s and early 2000s.
(36)
 Since the early 2000s the gold standard treatment has 
been a dual drug regimen consisting of a weekly injection of peg-IFN plus daily oral RBV.
(37)
 
This regimen has achieved SVR rates of 50% in genotype 1 disease and 70%-80% in other 
genotypes.
(38) 
 
Treatment of patients with this regimen was limited due to treatment contraindications an 
adverse toxicity profile and low SVR rates in patients with advanced fibrosis and prior 
treatment failure.
(36, 39)
 Almost all patients treated with peg-IFN experience significant side-
effects including; fatigue, flu-like symptoms, weight loss, seizures, peripheral neuropathy, 
bone marrow suppression and psychiatric symptoms.
(37)
 
 
3.6 New Drug Regimens 
In recent years new treatment agents have been developed. These directly acting anti-virals 
(DAAs) were initially added to the traditional peg-INF RBV regimen. Using DAAs 
combined with peg-INF and RBV results in improved SVR rates when compared with using 
peg-INF and RBV only.
(37)
 In 2012, two first generation DAAs, bocepravir and telaprevir, 
were approved for use and reimbursed in Ireland in triple therapy regimens with peg-INF and 
RBV. Subsequently several more DAAs have become or are due to become available 
including; simeprevir, sofosbuvir, daclatasvir and ledipasvir. 
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New DAA treatment regimens which do not contain peg-INF are now available. These 
regimens have been shown to achieve high SVR rates in several patient groups. The 
Canadian Agency for Drugs and Technologies in Health have undertaken a comprehensive 
review of both clinical and cost effectiveness of interferon-free regimens for use in genotype 
1 chronic hepatitis C.
(37)
 Of note Genotype 1 is the main genotype among the people with 
hepatitis C in Ireland.  
 
The review assessed ten relevant reports/studies. The review found that the studies reported 
that SVR was achieved in over 90% of patients who received sofosbuvir and ledipasvir, with 
or without RBV for 8, 12 or 24 weeks in treatment naïve and treatment experienced patients. 
SVR of over 90% was achieved in patients who received sofosbuvir and daclatasvir, with or 
without RBV for 12 or 24 weeks in treatment naïve and treatment experienced patients. In 
treatment experienced patients with cirrhosis, 100% of patients who received sofosbuvir and 
ledipasvir achieved SVR at 12 weeks. Lower SVR rates were seen in patients who received a 
sofosbuvir plus RBV regimen. Low levels of serious side effects and discontinuation were 
identified. This evidence suggests that high SVR rates can be attained with interferon-free 
DAA regimens in both treatment naïve and treatment experienced patients with genotype 1 
hepatitis C. However, there were no head to head trials comparing interferon-free regimens 
and those that contain interferon, making it difficult to compare such regimens.
(37)
 
 
3.7    Cost Impact and Affordability  
The budget impact of these new interferon-free DAA regimens is considerable due to the cost 
of the drugs and also the size of the population to be treated. 
 
Cost effectiveness Reviews 
Ireland 
In 2012, following an assessment of cost effectiveness; the NCPE recommended that two 
DAAs, protease inhibitors boceprevir and telaprevir were suitable for reimbursement in 
Ireland. These drugs were recommended for use in combination with Peg-IFN and RBV in 
patients with hepatitis C with genotype 1 disease. SVR rates showed improvement compared 
with previous treatment regimens. In 2014, the NCPE recommended the use of simeprevir as 
part of a triple therapy regimen with Peg-IFN and RBV for genotypes 1 and 4 in both 
treatment naive and treatment experienced patients. Several newer agents are in development, 
undergoing licensing and reimbursement decisions.  
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The NCPE has recently completed a report (October 2014) on the clinical and comparative 
effectiveness of sofosbuvir.  Sofosbuvir (Sovaldi)® is licensed for all genotypes of hepatitis 
C.  It is licensed in combination with peg-interferon and ribavirin and is the first DAA to be 
licensed with ribavirin alone (interferon free). The manufacturer presented many different 
scenarios across different genotypes stratified by cirrhosis status and previous treatment 
status.   
 
The NCPE review group considered that the clinical evidence used to support the application 
is associated with uncertainty, in particular in patients where a greater clinical need may be 
identified such as cirrhotic, decompensated cirrhosis and pre-and post-transplant patients. The 
review group also took into account the real world data presented on previous DAAs 
boceprevir and telaprevir where the effectiveness was less than that reported in the clinical 
trials.  There is insufficient data on sofosbuvir to indicate whether a similar trend will present 
with real world sofosbuvir data. 
 
The cost effectiveness of sofosbuvir is influenced greatly by the presence of cirrhosis and 
previous treatment.  In non-cirrhotic patients who have not been previously treated, 
sofosbuvir is not a cost effective treatment option.  In non-cirrhotic patients who have 
previously been treated, sofosbuvir + PR may be cost effective in genotype 3 patients if given 
for 12 weeks only.  In cirrhotic patients sofosbuvir is cost effective if given for 12 weeks 
however the Incremental cost-effectiveness ratio (ICER) increases above €45,000/QALY if 
given for 24 weeks in some scenarios. 
 
Currently the NCPE are assessing a dossier (submitted by Janssen) for simeprevir to be used 
with sofosbuvir.  The HTA will compare this combination with the second generation of 
drugs.  
 
A further submission for daclatasvir peg-interferon and ribavirin and daclatasvir with 
sofosbuvir was received at the end of November 2014. 
 
A single tablet regimen manufactured by Gilead Sciences Ltd combining sofosbuvir and 
ledipasvir was licensed by the European Medicines Agency in November 2014.   A further 
interferon free regimen manufactured by Abbvie is expected to be licensed in January 2015.  
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In 2014 the European Union’s Directorate General for Health and Consumers (SANCO) 
requested a summary of regional and national assessments of sofosbuvir. The summary report 
was created by EUnetHTA in collaboration with the Medicine Evaluation Committee 
(MEDEV). Ten countries (including Scotland, Germany, France, Netherlands) across Europe 
contributed to the report. Overall sofosbuvir was found to be effective as part of both 
interferon free and interferon containing multi-drug regimens. These regimens achieved high 
SVRs in several subgroups of hepatitis C patients including subgroups where interferon was 
not tolerated or contraindicated. Sofosbuvir was generally well-tolerated. While the 
magnitude of benefit varied considerably most countries (Spain, Scotland, Netherlands) 
agreed that sofosbuvir was of added value in the treatment of hepatitis C.  
 
The cost of sofosbuvir is considerable with a 12 week course costing from €40,475 to 
€57,000 in the reporting countries. Despite the cost, in most countries where cost-
effectiveness was taken into account, treatment regimens were judged to be cost-effective. 
Most countries found some or all scenarios cost effective however there were methodological 
issues highlighted in many of the assessments. It is difficult to assess these judgements as 
cost-effectiveness thresholds differ or were not explicitly defined. 
 
Recommendations following Health Technology Assessments in Other Jurisdictions 
National Institute for Health and Care Excellence (NICE) UK 
NICE recommended both telaprevir and boceprevir in combination with pegylated interferon 
and ribavirin for use in patients with genotype 1 in April 2012.  
 
In July 2014, NICE published an appraisal consultation document for sofosbuvir.  The draft 
recommendation from the committee was not to recommend sofosbuvir within its marketing 
authorisation for treating chronic hepatitis C in adults.  At that time, the committee 
recommended that NICE request further analyses from the manufacturer for sofosbuvir in 
combination with ribavirin, with or without peg-interferon alpha compared with peg-
interferon alpha and ribavirin in patients with genotype 1 and 3 in preparation for the second 
appraisal committee meeting.  Revised recommendations to the original July 
recommendations were published in August 2014 when a number of recommendations were 
made: 
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Sofosbuvir in combination with PR: 
a) Recommended for all patients with GT1 
b) Cirrhotic patients with GT3 TN 
c) Non-cirrhotic GT3 patients only is treatment experienced 
d) Not recommended for genotypes 4, 5 and 6 
 
Sofosbuvir in combination with ribavirin alone: 
a) Not recommended for genotypes 1, 4, 5 and 6 
b) Is recommended as an option for treating genotype 2 patients only if: 
a. they are TN and intolerant to or ineligible for interferon therapy or  
b. if they are treatment experienced, regardless of interferon eligibility 
c) Is recommended for patients with genotype 3 with cirrhosis’ 
 
The full appraisal document is anticipated in January 2015. 
 
Scottish Medicines Consortium (SMC), Scotland 
The SMC accepted both telaprevir and boceprevir in combination with pegylated interferon 
and ribavirin for use in patients with genotype 1 in 2011. 
 
In June 2014 sofosbuvir was accepted for restricted use within NHS Scotland for genotypes 
1-6.  Use in treatment naïve patients with genotype 2 is restricted to those ineligible for, or 
are unable to tolerate peg-interferon alpha.  Use of the 24 week interferon-free regimen of 
sofosbuvir, in combination with ribavirin, in patients with genotype 3, is restricted to those 
ineligible for or unable to tolerate peg-interferon alpha.   
 
The Pharmaceutical Benefits Advisory Committee (PBAC), Australia 
Tripe therapy regimens containing telaprevir or boceprevir with peg-interferon and ribavirin 
are recommended for restricted use in Australia by the PBAC. 
 
In July 2014 PBAC rejected the submission for sofosbuvir for the treatment of chronic 
hepatitis C on the basis of unacceptably high and likely underestimated cost-effectiveness and 
the high and likely underestimated budgetary impact on the Pharmaceutical Benefits Scheme.   
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Canadian Agency for Drugs and Technologies in Health (CADTH), Canada 
Telaprevir and boceprevir regimens were recommended for use only in patients with F2-F4 
liver status. 
 
CADTH has recommended that sofosbuvir be listed for the treatment of chronic hepatitis C 
virus infection in adult patients with compensated liver disease, including cirrhosis based on 
specific criteria for each genotype.  The clinical criteria are as follows: 
a) In genotype 1, sofosbuvir in combination with PR for patients with fibrosis stage F2-
F4 
b) In genotype 2 in combination with ribavirin for patients F2-F4 who are treatment-
experienced or have a medical contraindication to PR 
c) For genotype 3 patients in combination with RBV for patients with Stages F2-F4 and 
treatment-experienced and a medical contradiction to PR 
There are no recommendations relating to genotypes 4-6, and a price reduction was a 
condition of the recommendation.  In addition, it was stipulated that funding not exceed 12 
weeks for the treatment of patients with genotype 1 or 2 and 24 weeks for genotype 3.   
 
Institute for Quality and Efficiency in Healthcare (IQWiG), Germany 
The process in Germany allows unrestricted use of all drugs for the first year.  Assessment by 
IQWIG will assess whether the drug demonstrates incremental benefit over current treatment 
and if so the price is then agreed. 
 
In April 2014 IQWiG published their benefit assessment for sofosbuvir based on the extent 
and probability of added benefit.  The evaluation concluded that added benefit was not 
proven for genotypes 1 (& 1b), 2 (treatment naïve), 3, 4, 5 and 6.  They determined that in 
patients with genotype 2 who were treatment experienced, an indication of added benefit 
(extent not proven) was apparent from the evidence. 
 
Following a survey of European Union countries, it is clear that most countries have some 
form of restricted access to treatments based on prioritization criteria.  This is particularly the 
case for the newer generation DAAs including sofosbuvir.  Some European countries e.g. 
Poland have agreed to not reimburse sofosbuvir for any group.   
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The new DAAs facilitate shortened courses of treatment and are associated with higher 
sustained viral responses than previously achieved with relatively little toxicity.  Pan 
genotypic licenses have been granted for some of the agents (e.g. sofosbuvir) but not for all. 
The regimens have been successful in patients who have previously been difficult to treat, 
including those with cirrhosis, HIV co-infection and those who have undergone liver 
transplantation.  In general these agents are cost effective but the cost effectiveness varies in 
different genotypes and subgroups.  The clinical trials to date have demonstrated response 
rates up to 90% and some higher.  There is less data in some of these ‘difficult to treat’ 
groups and therefore observational evidence through real life use will be vital in determining 
whether the response rates achieved in trials will be realised in more heterogeneous 
populations. 
 
USA 
An economic evaluation was undertaken in the United States (US) to evaluate the cost-
effectiveness of sofosbuvir plus simeprevir compared with sofosbuvir plus RBV. The patients 
in this analysis included subgroups of treatment naïve, treatment experienced patients, 
interferon intolerant and interferon ineligible with genotype 1 disease. This evaluation found 
that sofosbuvir plus simeprevir was more cost-effective than sofosbuvir plus RBV in the US 
setting. 
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4. Drug Reimbursement Decision Process in Ireland 
 
4.1 Health Technology Assessment 
Health technology assessment (HTA) is a multidisciplinary activity that systematically 
examines the safety, clinical efficacy and effectiveness, cost and cost-effectiveness, 
organisational implications, social consequences, legal and ethical considerations of the 
application of a health technology.
(40) 
This is done in a systematic, transparent, unbiased and 
robust manner. Health technologies include pharmaceuticals, devices, diagnostics, 
procedures, care pathways and public health activities, as well as the systems within which 
health is protected and maintained.
(41)
 HTA acts as a bridge between evidence and policy-
making. It seeks to provide health policy-makers with accessible, useable and evidence-based 
information to guide their decisions about the appropriate use of technology and the efficient 
allocation of resources.
(40) 
 
The main issues that a HTA are concerned with are; 
 Does the technology work? 
 For whom does it work? 
 What is the benefit to the individual? 
 At what cost? 
 How does it compare to alternatives? 
 
In Ireland HTAs are undertaken by Health Information and Quality Authority (HIQA)  and 
the National Centre for Pharmacoeconomics (NCPE). The NCPE is responsible for 
pharmaceutical HTAs in Ireland. 
 
4.2 Drug reimbursement process 
In Ireland once a product is licensed for use, the relevant company can make an application 
for reimbursement to the HSE. The HSE has statutory responsibility for decisions on pricing 
and reimbursement of medicinal products under the Community Drug Schemes in accordance 
with the provisions of the Health (Pricing and Supply of Medicinal Goods) Act 2013.
(42)
 A 
reimbursement decision is made within 180 days of the application for reimbursement, 
subject to any necessary clock stops when additional information is sought from the 
company.  
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For a medicine to be reimbursed under the Community Drug Schemes, the supplier makes an 
application to the HSE under section 18 of the Health (Pricing and Supply of Medicinal 
Goods) Act 2013. As part of the reimbursement process the NCPE carries out an assessment 
and makes recommendations to the HSE. The approach includes two stages of review: 
 
1. Rapid review of a drug which is a review of abbreviated information on efficacy, 
safety and budget impact.  If there is uncertainty associated with any of these 
parameters the drug will be referred for a full assessment.  This process takes 2-4 
weeks. 
2. Full review of the cost effectiveness dossier requires the manufacturer to submit a full 
dossier of the clinical and cost effectiveness for review.  This process takes 90 days 
with a clock stop when the dossier is referred back for queries. 
 
Products that satisfy the agreed HTA criteria used in the Irish public health system, including 
a cost-effectiveness threshold of €45,000 per Quality Adjusted Life Year (QALY), are 
normally automatically added to the Reimbursement List by the HSE. 
 
If products do not meet the agreed HTA criteria, or uncertainty remains around clinical or 
cost-effectiveness evidence, the NCPE may not recommend in their favour. The NCPE can 
also recommend that a drug should not be reimbursed at the price quoted by the supplier.  
 
Exceptional products which fail to satisfy the €45,000/QALY threshold may still be put 
forward for reimbursement subject to further with the manufacturers. The NCPE appraisal 
informs the discussions between the HSE and the pharmaceutical supplier aimed at securing  
cost effective prices for drugs. Once negotiations are complete, the HSE Drugs Group 
considers a range of criteria including; clinical and cost-effectiveness, budget impacts and 
unmet needs, and makes recommendations to the HSE Leadership on whether new products 
which exceed the cost-effectiveness threshold should be reimbursed. The HSE Leadership 
team ultimately makes the reimbursement decision. 
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5. Proposed Multi-annual Pharmaceutical Treatment Programme 
 
5.1 Feasibility of a Multiannual Treatment Plan based on Clinical Prioritisation  
The new and innovative Direct Acting Antiviral drugs (DAA’s) provide Ireland with an 
opportunity to treat people with chronic hepatitis C infection effectively and consequently 
reduce the burden on the individuals, their families and communities and on health and social 
services. However although there is evidence that these drug regimens are clinically effective 
and cost effective, particularly for certain groups of patients with hepatitis C infection they 
are associated with very high pharmaceutical costs , which has a significant impact on 
affordability for the Irish taxpayer.  
 
The CMO in reviewing the issue of these new effective drug regimens with a significant cost 
impact proposed the development of a paper for the Minister for Health to assess the 
feasibility of a managed multiannual approach to treatment for patients with hepatitis C. It 
was proposed that this approach would ensure that drug treatment for patients with hepatitis 
C would be provided a consistent, fair, sustainable and affordable way. By implementing 
such an approach resources would be used effectively and efficiently to treat and cure as 
many patients within a managed budget as possible. Treatment is however only one element 
of a strategy that contributes to an ultimate goal of eradicating hepatitis C in the Irish 
population.   
 
This multiannual treatment approach should be based on good evidence of how to achieve 
optimal clinical outcomes for patients with hepatitis C. One of the methods suggested to 
optimise patient outcomes is through the use of clinical prioritisation to identify patients at 
greatest clinical risk. In the absence of a managed approach there is a risk that drug regimens 
would be prescribed on a case-by-case basis. This could result in a lack of prioritisation for 
treatment for patients with the highest clinical risk and that resources may not be managed 
effectively and efficiently. A multiannual approach allows for the projected costs of treatment 
to be spread out over a number of years while being based on clinical prioritisation criteria.  
 
An assessment of the feasibility of this approach was undertaken, informed by international 
and national evidence and expertise. The assessment shows that a multiannual approach 
based on clinical prioritisation is a feasible approach to undertake in Ireland for the provision 
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of drug treatments for patients with hepatitis C including new and emerging DAAs (this is 
explored in more detail in section 5.2 below).  The assessment and consultation also 
determined that such a treatment approach needs strong governance and management 
structures and robust clinical leadership and participation.  
 
In assessing the feasibility of a multiannual treatment plan a number of areas require review. 
These include, which treatment strategy delivers optimum outcomes for the patient and the 
health system and what information is available to design the treatment programme: 
specifically is there information on the clinical profile of the patient population and on the 
strength of the clinical network.   
 
Treatment Strategy 
Should the treatment strategy be a phased strategy and if so based on what criteria?  
Many health systems internationally are reviewing treatment strategies for drugs including 
those for hepatitis C that are very expensive and therefore pose serious capacity and 
affordability issues. One question is whether these health systems and services have the 
capacity to treat all individuals with hepatitis C in a short time frame? International 
experience and expertise suggests that this is a significant challenge for most health systems. 
To deliver such treatment in a short time frame would put significant demands on the services 
potentially requiring increased capacity with possible redirection of or addition of resources. 
A phased treatment strategy delivered over a number of years would spread the cost burden 
and allow for better management of resources. This would minimise any negative impact on 
the delivery of services and would ensure that the financing model for the treatment strategy 
is sustainable.  
 
 If the treatment strategy is based on phased treatment then criteria are needed to determine 
the treatment order.  A review of international research and evidence (including modelling 
data)  shows that strategies which take into account the stage and probability of progression 
of disease are likely to have a greater impact on outcomes than those which do not use this 
information. It also suggests that the optimum strategy depends upon the treatment regimens 
available and the characteristics of the population to be treated. 
 
Therefore in Ireland a risk based phased approach is proposed which will prioritise 
patients based on their clinical status for treatment.  
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Clinical Profile of Patient Population with Chronic hepatitis C 
In Ireland there is some good information, although with limitations, to allow for a clinical 
and risk profile of the population of patients with chronic hepatitis C to be described. This 
information supports a process for clinical prioritisation and phasing of treatment. As noted in 
Section 2 evidence and research in Ireland estimates a prevalence of chronic hepatitis C 
infection of between 20,000 – 30,000 people in the population. The clinical information 
available enables the estimation of the approximate numbers of patients who have been 
diagnosed and are engaged with hospital services. Clinical experts working in this field in 
Ireland have estimated the number of patients, from those who are actively engaged with the 
services, with the greatest clinical need. They have done this using information from the Irish 
Hepatitis C Outcomes and Research Network (ICORN) database and clinical information. 
This was determined using clinical prioritisation criteria based on international evidence and 
expertise. This process allows for an estimate of the number of patients who need treatment 
in the short to medium term and is useful in designing the services needed to deliver 
treatment. This information will continue to be essential in designing the services for 
delivery of the treatment programme.  
 
Clinical Network 
In Ireland there is a well-established clinical group that can support a national approach to 
clinical decisions making and the development of clinical pathways and guidelines.  The 
ICORN treatment registry currently provides information on the clinical status and 
demographic profile of patients with hepatitis C infection treated with DAA treatment 
regimens. This Treatment Registry is an important database that can be expanded to inform 
the development of future clinical pathways and guidelines in Ireland. 
 
The clinical services for hepatitis C infection are distributed across the country with eight 
designated centres of care in the larger hospitals in Dublin, Cork, Limerick, Kilkenny and 
Galway. These services can support the delivery of treatment in locations in all the major 
population centres and therefore will enable treatment services to be delivered to patients 
across Ireland. 
 
The evidence relating to the clinical effectiveness of any new drugs will increase as they are 
used more commonly and in different population groups e.g. population groups with different 
genotypes. In Ireland as part of the Hepatitis C Treatment Programme a Hepatitis C 
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Disease Register will be developed – building on the ICORN registry. This Register will 
monitor outcomes for patients who are treated with new and emerging drug regimens 
including sustained viral clearance, side effects and patient experience. Consequently it 
will provide important information on the clinical effectiveness of drug regimens in the 
different population groups in Ireland.  This Register should also include those patients who 
have not yet been treated. 
 
Drug Regimens 
Efficacy data for newer treatment regimens indicate that sustained viral clearances of up to 
90% are achievable depending on the patient’s baseline characteristics. As oral medications 
they are easier to take with fewer side effects and therefore more patients can tolerate the 
regimens with higher compliance rates.  
 
Cost Impact and Affordability  
In assessing the feasibility of a phased multiannual approach the current and future cost of 
drug regimens need to be taken into account. The new drug regimens are very expensive and 
could potentially lead to millions of euro being spent over the next few years. If there is a 
managed multiannual approach then this cost can be spread over a number of years. There is 
also opportunity within a managed approach for continued review and negotiation with 
pharmaceutical companies in relation to both existing drugs and also any emerging drug 
treatments. As part of the proposed treatment approach real world outcomes for Irish patients 
will continue to be collected in a Hepatitis C Register. Consequently this information will be 
available to inform treatment decisions both for individuals but also for groups within the 
hepatitis C population in Ireland. This will lead to more informed decision making on the 
most appropriate clinical pathways and drug treatments for patients and also inform drug 
reimbursement decisions.   
 
 
5.2 Clinical Management of Patients with hepatitis C 
To ensure that patients with the greatest clinical need are treated as a priority, patients should 
be assessed using clinical criteria. As a separate but important process when selecting the 
most appropriate and effective drug a patient’s clinical profile, for example genotype and 
their treatment history should also be taken into account. 
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Proposed Clinical Prioritisation Criteria for Treatment 
As noted earlier research from other countries and international experience and expertise 
suggests that when providing new drug treatments, DAAs, to patients with hepatitis C 
infection a strategy that treats those with the greatest clinical need as a priority can achieve 
better clinical outcomes 
(34)
 and this prioritisation is also in line with clinical guidance. 
(43, 44)
 
It is suggested that this approach reduces the clinical risk for those who are at highest risk of 
death or irreversible damage, thus reducing morbidity, mortality and reducing the need for 
liver transplantation.  
 
Internationally programmes for treating patients with chronic hepatitis C with the new DAAs 
for example the early access programme in the United Kingdom, have used clinical criteria to 
identify patients with the greatest clinical need so that they can be prioritised for treatment.  
Based on this international evidence and advice from clinical experts it is proposed that in 
Ireland the approach will be that patients with most clinical need will be prioritised for 
treatment with new and emerging drugs regimens.  The clinical criteria used to prioritise 
patients for treatment will evolve over the next few years. As new drug regimens and other 
interventions are developed and implemented and as the disease itself evolves over time the 
clinical criteria will need to reflect these changes.  
 
The clinical criteria set out for the Hepatitis C Treatment Programme should be regularly 
reviewed and developed by clinical experts and any changes in the clinical criteria 
implemented by the treatment programme.  
 
Given the decision to apply a clinical prioritisation approach the Department of Health asked 
clinical experts, through ICORN, to propose the initial clinical criteria for an Irish Hepatitis C 
Treatment Programme. The proposed clinical criteria were to focus on those patients with 
greatest clinical need and particularly to focus on those patients with a risk of death or 
irreversible damage within the next 12 months. These clinical criteria are based on 
international evidence and expertise.   
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The proposed clinical criteria for prioritisation of patients in Ireland are as follows: 
1. Evidence of present or previous decompensated cirrhosis defined as an episode of 
ascites, variceal bleeding, spontaneous bacterial peritonitis or encephalopathy. 
2. Child Pugh Score > or = 7 
3. Patients with compensated cirrhosis and platelets <100 x 109/L and albumin <35 
gm/dl  
4. Non-hepatic manifestation of HCV infection likely to lead to irreversible damage 
within 12 months AND intolerant of or failed to respond to pegylated interferon-
based treatment. 
5. Compensated Cirrhosis outside criteria 1-4 with accelerating factors including: HIV 
co-infection, Genotype 1b, Viral RNA titre, hepatic steatosis.  
Any expansion or development of these clinical prioritisation criteria should be based on new 
evidence and information; this is examined further in section 5.3.3.  
 
5.3 Governance and Management of a Hepatitis C Treatment Programme 
The implementation of a treatment strategy that ensures the phased treatment of patients with 
hepatitis C based on clinical prioritisation is complex with multiple components including the 
development and implementation of a clinical prioritisation process; the development of a 
Hepatitis C Disease Register to monitor outcomes; reimbursement processes and the 
development of governance and management structures. Therefore it is proposed that within 
the HSE governance structure a National Hepatitis C Treatment Programme is established to 
deliver on this programme and to provide the governance and management support required 
to achieve the goals of optimal clinical outcomes and effective use of resources. 
 
It is important that there is robust governance and management in relation to the 
implementation of the multiannual treatment programme. The HSE has the remit to provide 
all publicly funded health services in Ireland and therefore this treatment programme and 
reimbursement of the drug treatment regimens will be provided through HSE structures. The 
governance and management structure for this treatment programme should be in line with 
HSE governance structures, management processes and reimbursement decisions protocols.  
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5.3.1 Management Structures 
The HSE should put in place a programme manager who will be responsible for the 
implementation of the Hepatitis C Treatment Programme. The Programme Manager will 
report to the Director of Primary Care.  This hepatitis C programme manager will have 
responsibility and accountability for the delivery of all aspects of the Hepatitis C Treatment 
Programme.  
 
The Role of the Hepatitis C Treatment Programme Manager includes the development and 
implementation of the Hepatitis C Treatment Programme including: 
 Further developing  and maintaining a  Hepatitis C Disease Register  
 Developing and overseeing the operation of  clinical services to provide treatment for 
patients with hepatitis C 
 Monitoring the performance of the services 
 Developing and reporting on outcomes including patient outcomes  
 Planning services including development of new services to respond to new drug 
treatments 
 Contribute to the service planning process including preparing estimates  
 Ensuring services are delivered within HSE policies specifically within 
reimbursement policies. 
 
Hepatitis C Disease Register 
A Hepatitis C Disease Register will be integral to the governance and management structure 
of the Hepatitis C Treatment Programme. A  Hepatitis C Disease Register that records patient 
information and outcomes can be used to monitor the effectiveness of drug regimens and the 
treatment programme.  The Register will also support call and recall system. 
The Hepatitis C Disease Register variables should include: 
 patient characteristics e.g. gender, age, etc. 
 risk profile,  
 clinical status,  
 previous treatment history  
 current treatment 
 contraindications 
 Patient outcomes 
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Patient outcomes following treatment will be used to develop clinical pathways and clinical 
guidelines. These outcomes will inform analysis of the effectiveness and cost effectiveness of 
drug regimens including new and emerging drug regimens and they will also be used in 
future strategic negotiations with the pharmaceutical suppliers. 
 
5.3.2 Clinical Leadership 
A National Operational Clinical Lead should be appointed by the HSE to provide clear 
clinical leadership for the programme.  It is essential that there is clear clinical leadership and 
participation of clinicians in the Hepatitis C Treatment Programme. The Programme Manager 
should work with clinicians to ensure that there is good clinical input and clinical governance 
within the programme.  
 
The role of the National Operational Clinical Lead includes: 
 participation in the process for clinical prioritisation 
 Clinical lead for the Clinical Advisory Group of the Hepatitis C Treatment 
Programme 
 Clinical advice on the development and operation of the Hepatitis C Disease Register  
 development of Quality Assurance Reports for the Hepatitis C Treatment Programme  
 development  of clinical pathways including the continuous review of  clinical 
prioritisation criteria 
 development of clinical guidelines and  
 research  
 
5.3.3 Clinical Advisory Group for the Hepatitis C Treatment Programme 
A Clinical Advisory Group can review and provide oversight for decisions on clinical 
prioritisation and selection of appropriate drug treatment regimens for hepatitis C. This group 
can provide oversight for individual decisions or decisions about cohorts of patients. 
 
This Clinical Advisory Group membership should at a minimum include:  
 National Operational Clinical Lead for the Treatment Programme,  
 representation of treating clinicians,  
 independent clinical expert,  
 public health and  
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 HSE Medicines Management Programme. 
 
5.3.4. National Hepatitis C Treatment Programme Advisory Committee 
To provide overall oversight and advice to the Hepatitis C Treatment Programme the HSE 
should establish a National Hepatitis C Programme Advisory Committee. This committee 
builds on the experience and expertise of ICORN and will be supported by the Hepatitis C 
Treatment Programme.  
 
This committee advises the Hepatitis C Treatment Programme in relation to 
 the objectives and strategic direction of the Programme 
 the overall functioning of the programme and whether it is meeting its stated 
objectives 
 the Quality Assurance reports which will be focused on patient outcomes   
 new and emerging treatments for hepatitis C 
 treatment protocols, clinical pathways and guidelines 
 
Membership should at a minimum include: 
 Clinicians working in the treatment and management of patients with hepatitis C 
 Independent clinical expertise 
 Patient Representation 
 Medicine Management Programme 
 Public Health 
 Hep C Treatment Programme Manager 
 Department of Health 
 National Centre for Pharmacoeconomics 
 
The overall reporting structure of the management of the National Hepatitis C Programme is 
illustrated in figure 4 below: 
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Figure 4: Management Structure for the National Hepatitis C Programme 
 
 
5.3.5 Operational Governance Process for the Provision of Drug Regimens for 
Treatment of Hepatitis C  
The decision to provide drug treatment for patients with hepatitis C including new and 
emerging DAAs should have a clear decision pathway. This pathway should include a clear 
clinical prioritisation process, the registration of the patient on the Hepatitis C Disease 
Register and the HSE reimbursement process (see figure 5 below).  
 
Clinical Prioritisation Process 
Specialist Consultant Physicians and their teams will identify patients that fulfil the clinical 
prioritisation criteria. The team will ensure that all the relevant patient information is 
provided and the patient is entered onto the Hepatitis C Disease Register. (This information 
can be collated using information collected on a registration form (based on the ICORN 
registration form) and other clinical information.  
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The decision process for selection of appropriate treatment regimens includes application of 
clinical prioritisation criteria and is also informed by the patient’s clinical profile (e.g. 
genotype) and their treatment history. 
 
The Clinical Advisory Group provides oversight for decisions on clinical prioritisation and 
selection of appropriate drug treatment regimens for hepatitis C. This group provides 
oversight for individual decisions or decisions about cohorts of patients. 
 
Following the clinical prioritisation process if patients fulfil the clinical criteria then the next 
step involves meeting HSE reimbursement requirements. These include: 
 prescription of DAAs is restricted to Specialised Consultant Physicians. 
 the provision of DAAs  requires pre-authorisation as per the process outlined in 
Diagram1 
 In order for patients to be reimbursed they must have a valid GMS (Medical card) 
number or a DPS (Drugs Payment Scheme) number or a Health (Amendment) Act 
care number. 
 A valid GMS. HAA or DPS number will be required for reimbursement.  If this is not 
in place the patient should be advised to register for the appropriate scheme with the 
HSE. 
 DAAs are currently dispensed through hospital pharmacies 
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Figure 5: HSE Reimbursement Pathway  
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6. Conclusions 
In Ireland, as in other countries hepatitis C infection is a significant public health problem. 
There is a growing burden of disease associated with chronic hepatitis C infection for the 
individual patients, their families, society and the health and social services. However there 
are also opportunities with new and innovative drug treatments coming onto the market. 
There is evidence that these new drug treatments are clinically effective in trials particularly 
for some groups of patients with specific genotypes and there is also some early evidence that 
they are effective in real world treatments. As these drugs are used in treating more patients 
with different characteristics the evidence of their clinical effectiveness will build. It is 
therefore important that treatment outcomes are measured and monitored to add to this 
evidence base. However perhaps the greatest challenge for health systems in relation to these 
new drugs is their high cost. 
 
Because of these issues the Department of Health undertook an assessment of the feasibility 
of a managed treatment approach – based on clinical prioritisation and phasing treatment over 
a number of years. This managed approach would allow for these new drugs to be provided 
to those with the greatest clinical need as a priority, while monitoring their clinical outcomes 
so as to ensure that patients receive the most clinically and cost effective drug treatment.  
 
It was determined from the assessment that this would be a feasible approach to take as there 
is: a clear understanding of the clinical profile of the patients in Ireland with chronic hepatitis 
C infection, the presence of a good clinical network to be able to deliver the treatment and 
develop clinical pathways and guidelines and a treatment register already in place that can be 
built on to become a disease register to monitor the outcomes of patients treated with the new 
drug regimens. The assessment also indicated that for this treatment strategy to work it 
required strong governance and management structures. 
 
 It is therefore recommended that the HSE establishes a Hepatitis C Treatment Programme 
with a strong governance and management structure within the HSEs governance and 
management structures to deliver on this treatment plan.  
 
 A managed approach together with a strong governance structure will assist the HSE in 
negotiations with the pharmaceutical companies on the price of drugs. These negotiations 
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will be informed by the patient population profile, real world patient outcomes and the 
availability of a range of new and emerging drug treatments.  The intention is to provide drug 
treatment to those with greatest clinical need as a priority and, dependent on cost effective 
drug treatments being procured by the HSE, treating as many patients as possible with the 
available resources. This approach will impact on the prevalence of hepatitis C in a relatively 
shorter period of time and will mean more patients with hepatitis C will be treated sooner. 
This is an important component in ultimately working towards eradication of hepatitis C in 
the Irish population.  
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Appendix 1: Terms of Reference for the Group 
 
Terms of Reference for the Group  
 To advise on the implementation of a treatment strategy including timelines. 
 To advise on the development of a treatment strategy that incorporates existing, new 
and emerging treatment regimes. 
 To advise on the development of a Public Health Plan for the management and 
treatment of Hepatitis C  
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